CONCLUSIONS: Our findings support a significant polygenic basis for TRD, highlighting genetic and phenotypic distinctions from non-TRD. We demonstrate that different TRD(p) endpoints are enriched with various spectra of psychiatric genetic liability, offering insights into pharmacogenomics and TRD’s complex genetic architecture.
